Ryanodine receptor 1-mediated Ca²⁺ signaling and mitochondrial reprogramming modulate uterine serous cancer malignant phenotypes.

ABSTRACT:

Background

Uterine serous cancer (USC) is the most common non-endometrioid subtype of uterine cancer, and is also the most aggressive. Most patients will die of progressively chemotherapy-resistant disease, and the development of new therapies that can target USC remains a major unmet clinical need. This study sought to determine the molecular mechanism by which a novel unfavorable prognostic biomarker ryanodine receptor 1 (RYR1) identified in advanced USC confers their malignant phenotypes, and demonstrated the efficacy of targeting RYR1 by repositioned FDA-approved compounds in USC treatment.

Methods

TCGA USC dataset was analyzed to identify top genes that are associated with patient survival or disease stage, and can be targeted by FDA-approved compounds. The top gene RYR

SUBMITTER: Zhang L 

PROVIDER: S-EPMC9373370 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature